查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014689

基因組工程市場：按技術、產品、應用和最終用戶分類－2026-2032年全球市場預測

Genome Engineering Market by Technology, Product, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因組工程市值將達到 84.8 億美元，到 2026 年將成長到 98.3 億美元，到 2032 年將達到 242.4 億美元，複合年成長率為 16.17%。

主要市場統計數據
基準年 2025 84.8億美元
預計年份：2026年 98.3億美元
預測年份 2032 242.4億美元
複合年成長率 (%) 16.17%

全面且策略性地概述了基因組工程的進展、相關人員的優先事項以及影響短期決策的營運挑戰。

基因組工程正處於科學進步、商業性機會和監管交匯的關鍵時期。過去十年，可程式設計核酸酶系統和遞送方法的改進加速了基因組工程轉化為實用化。同時，生物資訊學和自動化技術的同步發展也加強了從發現到實用化的回饋循環。本執行摘要概述了當前情勢，闡明了關鍵促進因素和限制因素，並探討了其對研究機構、產業界和公共等各相關人員的影響。

對推動基因組工程競爭格局和策略重點重組的技術進步、監管調整和數據基礎設施成熟度進行分析概述。

基因組工程的現狀正經歷著一場變革，其驅動力來自科學進步、不斷演進的監管範式以及在治療、農業和工業生物技術領域日益廣泛的商業性應用。作為此技術的核心，可程式核酸酶平台已從早期原型發展到包含多重編輯、高精度變異體以及整合CRISPR與其他互補技術的混合系統。這些創新降低了脫靶效應，擴大了可編輯位點的範圍，並推動了更雄心勃勃的治療和農業計畫。同時，遞送科學（涵蓋物理、病毒和非病毒方法）在特異性和有效載荷能力方面也取得了進步，從而重塑了開發人員的專案設計決策。

對近期美國關稅措施如何重塑基因組工程相關人員的供應鏈韌性、籌資策略和跨境合作進行重點評估。

美國近期實施的關稅調整和貿易措施給支持基因組工程研發的全球供應鏈帶來了明顯的壓力。這些措施改變了進口設備、試劑和組件的成本計算方式，促使許多相關人員重新評估籌資策略。由於關稅的影響，依賴進口的專用電穿孔設備、顯微注射設備和某些前置作業時間類別可能會導致成本增加和交貨週期延長，這迫使採購負責人探索替代方案，例如供應商網路多元化和近岸外包。

一種基於細分的複雜分析，揭示了技術分類、產品類型、應用和最終用戶之間的相互作用，從而定義了差異化的策略機會和風險。

精細化的市場區隔觀點能夠清楚地展現整個基因組工程生態系中需求、產能和投資的交會點。依技術分析時，必須了解主要核酸酶家族的市場狀況，包括 CRISPR 系統、Meganucleases酶、活化因子樣效應核酸酶和鋅指核酸酶。此外，CRISPR 又細分為 Cas12、Cas9 和 Cpf1 三種變體，每種變體都展現出獨特的性能和應用特性。從產品角度來看，市場涵蓋儀器、試劑和耗材，以及軟體和服務。在儀器領域，電穿孔和顯微注射系統等專用平台驅動關鍵的工作流程；試劑和耗材包括遞送試劑、gRNA 組分、各種試劑盒和酵素。軟體和服務則涵蓋了數據分析和設計軟體等關鍵功能，這些軟體能夠加速藥物發現過程。

從全面的區域觀點解釋美洲、歐洲、中東和非洲以及亞太地區如何展現出不同的產能叢集、監管路徑和商業化動態。

區域趨勢對基因組工程領域的投資流動、人才分佈、監管方式和商業性化模式都產生了顯著影響。美洲是轉化研究活動和創業投資資金的中心，擁有強大的臨床開發平臺和大規模生物技術叢集，能夠促進從藥物發現到臨床檢驗的快速迭代。該地區還擁有先進的生物製藥製造生態系統和緊密的合約研發服務供應商網路，從而加快了商業化進程。

對儀器、試劑、軟體和治療藥物開發領域領導地位的競爭定位、合作模式和能力組合進行了深入評估。

基因組工程領域的競爭動態由眾多參與者共同塑造，其中包括傳統儀器製造商、專業試劑供應商、軟體和生物資訊學創新者，以及致力於開發治療藥物的敏捷生物技術公司。主要企業憑藉其平台廣度、專有的遞送技術、整合的分析能力以及透過完善的品質系統支援符合監管要求的開發流程的能力而脫穎而出。隨著終端用戶越來越傾向於選擇能夠降低整合風險並縮短結果獲取時間的捆綁式解決方案，整合儀器、試劑和服務優勢的協作生態系統正逐漸成為常態。

為高階主管提供可操作的策略建議，以加強供應鏈、儘早納入監管證據、擴大數位化和夥伴關係關係能力，從而確保市場領導地位。

產業領導企業應優先採取一系列措施，以平衡短期業務永續營運和長期平台差異化。首先，經營團隊必須透過採購多元化、建立關鍵耗材的區域性生產管道以及對專用設備和遞送試劑採取雙重採購策略來增強供應鏈的靈活性。這將使他們能夠在保持實驗步伐的同時，降低政策變化和物流中斷帶來的風險。

我們透過透明、多方面的調查方法確保獲得可靠的見解，該方法結合了專家訪談、文獻整合、專利和臨床環境分析以及迭代檢驗。

本執行摘要的研究採用了一種結構化、多維度的研究方法，結合了定性研究、嚴謹的二手研究以及證據的迭代檢驗驗證。一手資料包括對各領域專家的訪談，涵蓋學術研究人員、產業科學家、監管事務專業人員和商業領袖，從而深入了解技術採納、營運限制和策略意圖等方面的細微觀點。二手研究則納入了同行評審文獻、專利申請、臨床試驗註冊資訊、企業技術揭露以及公開的監管指南，以檢驗技術性能和合規要求的趨勢並識別關鍵轉折點。

這項權威的綜合分析強調，整合技術、營運和監管策略對於將基因組工程創新轉化為永續的商業性和社會影響至關重要。

基因組工程領域正從概念驗證（PoC）階段邁向更廣泛的商業性應用，但其特徵仍是技術多樣性、監管複雜性和不斷變化的供應鏈格局。相關人員的成功取決於整合技術創新、營運韌性和監管前瞻性的能力。隨著基因組工程在治療、農業和工業生物技術領域的應用不斷擴展，那些開發差異化解決方案、投資計算和自動化能力並積極管理採購和生產風險的組織將更有利於獲取價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：基因組工程市場：依技術分類

  • CRISPR系統
    • CRISPR/Cas12
    • CRISPR/Cas9
    • CRISPR/Cpf1
  • Meganucleases
  • 轉錄活化因子樣效應核酸酶
  • 鋅指核酸酶

第9章：基因組工程市場：依產品分類

  • 裝置
    • 電穿孔系統
    • 顯微注射系統
  • 試劑和耗材
    • 遞送試劑
    • 細胞RNA成分
    • 試劑盒酶
  • 軟體服務
    • 數據分析服務
    • 設計軟體

第10章：基因組工程市場：依應用領域分類

  • 農業和畜牧業
    • 作物改良
    • 牲畜改良
  • 診斷
    • 伴隨診斷
    • 基因檢測
  • 工業生物技術
    • 生質燃料生產
    • 酵素工程
  • 研究
    • 基礎研究
    • 目標檢驗
  • 治療藥物
    • Exovivo 編輯
    • 體內編輯

第11章：基因組工程市場：依最終用戶分類

  • 學術和研究機構
  • 合約研究機構
  • 製藥和生物技術公司

第12章：基因組工程市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：基因組工程市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：基因組工程市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因組工程市場

第16章：中國基因組工程市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AgBiome, Inc.
  • Agilent Technologies, Inc.
  • BASF SE
  • Bayer AG
  • Benson Hill, Inc.
  • Calyxt, Inc.
  • Cibus, Inc.
  • Corteva Agriscience, Inc. by DuPont de Nemours, Inc
  • Creative Biogene
  • Danaher Corporation
  • Elo Life Systems
  • GenScript Biotech Corporation
  • Groupe Limagrain SA
  • Lonza Group AG
  • Merck KGaA
  • New England Biolabs, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-437E9896A515

The Genome Engineering Market was valued at USD 8.48 billion in 2025 and is projected to grow to USD 9.83 billion in 2026, with a CAGR of 16.17%, reaching USD 24.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.48 billion
Estimated Year [2026] USD 9.83 billion
Forecast Year [2032] USD 24.24 billion
CAGR (%) 16.17%

A comprehensive and strategic introduction that contextualizes genome engineering advances, stakeholder priorities, and operational imperatives shaping near-term decisions

Genome engineering stands at a pivotal juncture where scientific advances intersect with commercial opportunity and regulatory scrutiny. Over the past decade, refinements in programmable nuclease systems and delivery modalities have accelerated translational momentum, while parallel progress in bioinformatics and automation has tightened the feedback loop between discovery and deployment. This executive summary frames the present landscape, articulates core drivers and constraints, and synthesizes implications for stakeholders across research institutions, industry, and public policy arenas.

The sector's current dynamics are shaped by converging vectors: technological maturation of editing tools, rising demand for precision therapeutics and agricultural innovations, and evolving regulatory expectations around safety and ethical governance. These forces create a high-velocity environment in which strategic clarity matters. As a result, leaders must balance near-term operational priorities-such as supply chain continuity and reagent quality assurance-with longer-term investments in platform differentiation and regulatory intelligence. By understanding these trade-offs, organizations can design roadmaps that are resilient to external shocks while capitalizing on accelerating scientific capabilities.

This introduction establishes the conceptual framework for the analysis that follows. It highlights the need for integrated strategies that combine technical excellence, commercial rigor, and proactive stakeholder engagement to sustain competitive advantage in genome engineering.

An analytical synthesis of technological evolution, regulatory recalibration, and data infrastructure maturation reshaping competitive dynamics and strategic priorities in genome engineering

The landscape of genome engineering is undergoing transformative shifts driven by scientific refinements, evolving regulatory paradigms, and heightened commercial application across therapeutics, agriculture, and industrial biotechnology. At the technological core, programmable nuclease platforms have diversified beyond early prototypes to include multiplexed editing, improved fidelity variants, and hybrid systems that integrate CRISPR with complementary technologies. These innovations reduce off-target effects and expand the range of editable loci, enabling more ambitious therapeutic and agronomic programs. Simultaneously, delivery science-spanning physical, viral, and nonviral approaches-has progressed in specificity and payload capacity, reshaping project design decisions across developers.

Regulatory frameworks are also in flux, with agencies moving toward more detailed guidance on clinical trial design, biodistribution analysis, and postmarket surveillance. This trend compels companies to embed regulatory evidence generation earlier in development cycles, increasing development complexity but also creating opportunities for differentiated product positioning based on robust safety and efficacy datasets. Moreover, bioinformatics and data analysis services are becoming essential to scale discovery and ensure reproducibility, altering the value chain and increasing demand for integrated software and analytics platforms.

Collectively, these shifts favor actors who can combine deep technical capabilities with regulatory foresight and scalable data infrastructure. Organizations that align internal R&D priorities, strategic partnerships, and manufacturing readiness with these shifts will be best positioned to translate innovation into durable commercial outcomes.

A focused appraisal of how recent United States tariff measures have reshaped supply chain resilience, procurement strategies, and cross-border collaboration for genome engineering stakeholders

Recent tariff policy adjustments and trade measures implemented in the United States have exerted measurable pressure on global supply chains that support genome engineering research and product development. These measures have altered the cost calculus for imported instruments, reagents, and components, and have prompted many stakeholders to reassess sourcing strategies. Import dependencies for specialized electroporation equipment, microinjection devices, and certain reagent categories can create exposure to tariff-driven cost increases and lead times, prompting procurement managers to explore diversified supplier networks and nearshoring alternatives.

Beyond procurement, tariffs influence collaborative arrangements and partnership geographies. Project timelines that rely on cross-border transfers of biological materials, equipment, or custom components must now incorporate additional customs documentation and potential inspection delays, which can impede sample mobility and slow iterative experimental cycles. For contract research organizations and instrument manufacturers, the cumulative effect is an imperative to redesign logistics workflows, build buffer inventories for critical consumables, and negotiate long-term supplier agreements that mitigate price volatility.

In response, many stakeholders are accelerating investments in domestic manufacturing capacity, local technical support networks, and redundant supply channels to preserve operational continuity. These adaptations enhance resilience but may also reallocate capital away from core R&D activities. Consequently, executive teams must weigh the trade-offs between short-term operational security and long-term innovation investment, while proactively engaging with policymakers to articulate industry needs and prioritize predictable trade conditions that underpin scientific advancement.

A nuanced segmentation-driven analysis revealing how technology classes, product types, applications, and end users interact to define differentiated strategic opportunities and risks

A granular segmentation lens clarifies where demand, capability, and investment converge across the genome engineering ecosystem. When analyzing by technology, the market must be understood across major nuclease families including CRISPR systems, meganucleases, transcription activator-like effector nucleases, and zinc finger nucleases, with CRISPR further differentiated into Cas12, Cas9, and Cpf1 variants, each exhibiting distinct performance and application profiles. From a product perspective, the landscape includes instruments, reagents and consumables, and software and services; within instruments, specialized platforms such as electroporation and microinjection systems drive key workflows, while reagents and consumables encompass delivery reagents, gRNA components, and a range of kits and enzymes, and software and services cover critical capabilities like data analysis and design software that accelerate discovery.

Application-focused segmentation reveals differentiated priorities across agriculture and animal sectors, diagnostics, industrial biotechnology, research, and therapeutics. Agriculture and animal applications range from crop improvement to livestock modification and demand unique regulatory and deployment strategies, whereas diagnostics span companion diagnostics and genetic testing with immediate clinical utility. Industrial biotech applications such as biofuel production and enzyme engineering leverage editing to enhance process strains and biocatalysts. Research use cases, from basic science to target validation, emphasize throughput and reproducibility, while therapeutic development differentiates between ex vivo and in vivo editing programs, each with distinct delivery and regulatory requirements. Finally, end-user segmentation includes academic and research institutes, contract research organizations, and pharmaceutical and biotechnology companies, and each end-user type prioritizes different combinations of performance, cost, and compliance support.

Viewing the ecosystem through these intersecting segmentation axes enables more precise strategic choices for product development, commercial targeting, and partnership orchestration, and underscores the necessity of tailored go-to-market approaches for each subsegment.

A comprehensive regional perspective explaining how the Americas, Europe Middle East and Africa, and Asia-Pacific exhibit distinct capability clusters, regulatory paths, and commercialization dynamics

Regional dynamics exert a strong influence on investment flows, talent distribution, regulatory approaches, and commercial adoption patterns across the genome engineering sector. In the Americas, there is a concentration of translational activity and venture funding, together with robust clinical development pipelines and sizable biotech clusters that support rapid iteration between discovery and clinical validation. This region also exhibits advanced manufacturing ecosystems for biologics and a dense network of contract research and development service providers that accelerate commercialization timelines.

Across Europe, the Middle East, and Africa, regulatory environments are heterogeneous, with several jurisdictions advancing comprehensive frameworks for gene editing trials and environmental release, while others are in earlier stages of policy formulation. This mosaic creates both challenges and opportunities for developers seeking pan-regional strategies; it incentivizes modular regulatory plans and selective country-level pilots that can validate safety and efficacy under different governance regimes. Additionally, Europe's strong base in precision breeding and agricultural science positions it as an important arena for non-therapeutic applications.

The Asia-Pacific region is characterized by rapid capacity building, large-scale agricultural innovation programs, and expanding biotech manufacturing. Many markets in this region are accelerating adoption of genome editing in both agriculture and therapeutics, supported by significant public-sector initiatives and growing private investment. Talent availability and manufacturing scale advantage in certain countries create attractive hubs for clinical manufacturing and reagent production, while market access strategies must account for varying regulatory timelines and intellectual property environments. Understanding these regional distinctions is critical for designing localization strategies, selecting strategic partnership geographies, and prioritizing market entry sequencing.

An insightful appraisal of competitive positioning, collaborative models, and capability combinations that define leadership in instruments, reagents, software, and therapeutics development

Competitive dynamics in the genome engineering sector are shaped by a blend of legacy instrument manufacturers, specialized reagent suppliers, software and bioinformatics innovators, and nimble biotechnology firms pursuing therapeutic pipelines. Leading organizations differentiate through platform breadth, proprietary delivery technologies, integrated analytics, and the ability to support regulated development pathways with robust quality systems. Collaborative ecosystems that combine strengths across instruments, reagents, and services are becoming normative, as end users increasingly prefer bundled solutions that reduce integration risk and speed time to result.

Strategic partnerships, licensing arrangements, and co-development agreements remain central to how value is created. Companies that offer interoperable hardware and reagents, or that can provide validated workflows for specific applications such as ex vivo editing or agricultural trait engineering, capture downstream value by lowering technical barriers for adopters. At the same time, firms that invest in computational design tools and data analysis services gain an edge by enabling higher-throughput and higher-confidence editing campaigns, which are particularly valuable in target validation and therapeutic candidate optimization.

Market entrants and incumbents alike must also navigate competitive pressures from open-source communities and academic innovation, which continue to contribute foundational methods and tooling. The firms that win will be those that combine strong IP strategies with collaborative channels to academia, scalable manufacturing capacity, and a service-oriented approach that meets the compliance and support expectations of enterprise customers.

Actionable strategic recommendations for executives to strengthen supply chains, embed regulatory evidence early, and scale digital and partnership capabilities to secure market leadership

Industry leaders should pursue a set of prioritized actions that reconcile near-term operational resilience with long-term platform differentiation. First, executives must fortify supply chain agility by diversifying sourcing, establishing regional manufacturing options for critical consumables, and adopting dual-sourcing strategies for specialized instruments and delivery reagents. This reduces exposure to policy shifts and logistical disruptions while preserving experimental cadence.

Second, organizations should integrate regulatory evidence generation into early-stage development plans by investing in robust safety assays, standardized biodistribution studies, and preemptive compliance documentation. Doing so will shorten review cycles and enhance sponsor credibility with regulators and payers. Third, companies should accelerate investments in digital infrastructure-design software, data analysis pipelines, and laboratory automation-to scale throughput, improve reproducibility, and enable iterative learning across projects. Such investments drive efficiency gains and magnify the value of experimental datasets.

Fourth, strategic partnerships must be structured to combine complementary strengths, such as linking advanced delivery platforms with computational design capabilities and validated manufacturing partners. Fifth, talent strategies should prioritize cross-disciplinary skill sets that blend molecular biology, bioinformatics, regulatory science, and manufacturing expertise, and leaders should create career pathways that retain this specialized talent. Lastly, stakeholder engagement-transparent dialogue with regulators, payers, patient groups, and agricultural constituencies-will safeguard social license to operate and smooth pathways to adoption. Implementing these actions in concert positions organizations to convert technological promise into sustainable market leadership.

A transparent multi-method research methodology combining expert interviews, literature synthesis, patent and clinical landscape analysis, and iterative triangulation to ensure robust findings

The research underpinning this executive summary was developed through a structured, multi-method approach combining primary qualitative inquiry, rigorous secondary analysis, and iterative triangulation of evidence. Primary inputs included interviews with domain experts spanning academic investigators, industry scientists, regulatory affairs professionals, and commercial leaders, which provided nuanced perspectives on technology adoption, operational constraints, and strategic intent. Secondary research incorporated peer-reviewed literature, patent filings, clinical trial registries, company technical disclosures, and publicly available regulatory guidance to validate trends and identify inflection points in technology performance and compliance requirements.

Data synthesis relied on cross-validation techniques to reconcile divergent viewpoints and to surface high-confidence insights. Key analytical methods included thematic coding of qualitative interviews, comparative assessment of technology performance metrics, and scenario mapping to understand policy and market contingencies. Patent landscape analysis and clinical pipeline reviews were used to identify innovation trajectories and to assess the maturity of specific platforms and delivery modalities. The methodology emphasized transparency and reproducibility, documenting data sources and analytical assumptions to enable subscribers to understand the basis for conclusions.

Where appropriate, expert reviewers provided validation of technical interpretations and helped shape practical recommendations. This layered approach ensures that findings reflect both empirical evidence and the tacit knowledge of practitioners actively engaged in genome engineering development.

A conclusive synthesis emphasizing that integrated technical, operational, and regulatory strategies are essential to convert genome engineering innovations into durable commercial and societal impact

The genome engineering domain is moving from proof-of-concept toward broader commercial application, yet it remains characterized by technological heterogeneity, regulatory complexity, and evolving supply chain landscapes. Success for stakeholders will hinge on the ability to integrate technical innovation with operational resilience and regulatory foresight. Organizations that develop differentiated delivery solutions, invest in computational and automation capabilities, and proactively manage procurement and manufacturing risk will be better positioned to capture value as applications expand across therapeutics, agriculture, and industrial biotechnology.

Moreover, partnerships and ecosystem plays will continue to shape who captures downstream value. Firms that offer validated workflows, comprehensive support services, and interoperable platforms will reduce adoption friction and build customer trust. Concurrently, a proactive approach to regulatory engagement and public communication will be essential to navigate societal expectations and ensure sustainable adoption. In sum, translating scientific capabilities into real-world impact requires a deliberate strategy that aligns R&D investments, commercial models, and stakeholder engagement to the specific demands of each application and region.

This conclusion underscores the need for integrated action: technical excellence must be matched with supply chain strategy, regulatory preparedness, and commercial acumen to realize the full potential of genome engineering innovations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genome Engineering Market, by Technology

  • 8.1. CRISPR Systems
    • 8.1.1. CRISPR/Cas12
    • 8.1.2. CRISPR/Cas9
    • 8.1.3. CRISPR/Cpf1
  • 8.2. Meganucleases
  • 8.3. Transcription Activator Like Effector Nucleases
  • 8.4. Zinc Finger Nucleases

9. Genome Engineering Market, by Product

  • 9.1. Instruments
    • 9.1.1. Electroporation Systems
    • 9.1.2. Microinjection Systems
  • 9.2. Reagents & Consumables
    • 9.2.1. Delivery Reagents
    • 9.2.2. gRNA Components
    • 9.2.3. Kits & Enzymes
  • 9.3. Software & Services
    • 9.3.1. Data Analysis Services
    • 9.3.2. Design Software

10. Genome Engineering Market, by Application

  • 10.1. Agriculture & Animal
    • 10.1.1. Crop Improvement
    • 10.1.2. Livestock Modification
  • 10.2. Diagnostics
    • 10.2.1. Companion Diagnostics
    • 10.2.2. Genetic Testing
  • 10.3. Industrial Biotech
    • 10.3.1. Biofuel Production
    • 10.3.2. Enzyme Engineering
  • 10.4. Research
    • 10.4.1. Basic Research
    • 10.4.2. Target Validation
  • 10.5. Therapeutics
    • 10.5.1. Ex Vivo Editing
    • 10.5.2. In Vivo Editing

11. Genome Engineering Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Genome Engineering Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genome Engineering Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genome Engineering Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Genome Engineering Market

16. China Genome Engineering Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AgBiome, Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. BASF SE
  • 17.8. Bayer AG
  • 17.9. Benson Hill, Inc.
  • 17.10. Calyxt, Inc.
  • 17.11. Cibus, Inc.
  • 17.12. Corteva Agriscience, Inc. by DuPont de Nemours, Inc
  • 17.13. Creative Biogene
  • 17.14. Danaher Corporation
  • 17.15. Elo Life Systems
  • 17.16. GenScript Biotech Corporation
  • 17.17. Groupe Limagrain S.A.
  • 17.18. Lonza Group AG
  • 17.19. Merck KGaA
  • 17.20. New England Biolabs, Inc.
  • 17.21. PerkinElmer, Inc.
  • 17.22. QIAGEN N.V.
  • 17.23. Takara Bio Inc.
  • 17.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOME ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOME ENGINEERING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENOME ENGINEERING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENOME ENGINEERING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOME ENGINEERING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENOME ENGINEERING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENOME ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENOME ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENOME ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CAS12, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CAS12, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CAS12, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CPF1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CPF1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CRISPR/CPF1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENOME ENGINEERING MARKET SIZE, BY MEGANUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOME ENGINEERING MARKET SIZE, BY MEGANUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENOME ENGINEERING MARKET SIZE, BY MEGANUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOME ENGINEERING MARKET SIZE, BY TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOME ENGINEERING MARKET SIZE, BY TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOME ENGINEERING MARKET SIZE, BY TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ELECTROPORATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ELECTROPORATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ELECTROPORATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOME ENGINEERING MARKET SIZE, BY MICROINJECTION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENOME ENGINEERING MARKET SIZE, BY MICROINJECTION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOME ENGINEERING MARKET SIZE, BY MICROINJECTION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DELIVERY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DELIVERY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DELIVERY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOME ENGINEERING MARKET SIZE, BY GRNA COMPONENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENOME ENGINEERING MARKET SIZE, BY GRNA COMPONENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOME ENGINEERING MARKET SIZE, BY GRNA COMPONENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENOME ENGINEERING MARKET SIZE, BY KITS & ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOME ENGINEERING MARKET SIZE, BY KITS & ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOME ENGINEERING MARKET SIZE, BY KITS & ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DESIGN SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DESIGN SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DESIGN SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOME ENGINEERING MARKET SIZE, BY LIVESTOCK MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENOME ENGINEERING MARKET SIZE, BY LIVESTOCK MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOME ENGINEERING MARKET SIZE, BY LIVESTOCK MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENOME ENGINEERING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOME ENGINEERING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENOME ENGINEERING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOME ENGINEERING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENOME ENGINEERING MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOME ENGINEERING MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENOME ENGINEERING MARKET SIZE, BY BIOFUEL PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOME ENGINEERING MARKET SIZE, BY BIOFUEL PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENOME ENGINEERING MARKET SIZE, BY BIOFUEL PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ENZYME ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ENZYME ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ENZYME ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENOME ENGINEERING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOME ENGINEERING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENOME ENGINEERING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENOME ENGINEERING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOME ENGINEERING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENOME ENGINEERING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOME ENGINEERING MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENOME ENGINEERING MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOME ENGINEERING MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENOME ENGINEERING MARKET SIZE, BY EX VIVO EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOME ENGINEERING MARKET SIZE, BY EX VIVO EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENOME ENGINEERING MARKET SIZE, BY EX VIVO EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOME ENGINEERING MARKET SIZE, BY IN VIVO EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENOME ENGINEERING MARKET SIZE, BY IN VIVO EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOME ENGINEERING MARKET SIZE, BY IN VIVO EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOME ENGINEERING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENOME ENGINEERING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOME ENGINEERING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENOME ENGINEERING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOME ENGINEERING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENOME ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS GENOME ENGINEERING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENOME ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GCC GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GCC GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. GCC GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 252. GCC GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. GCC GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. GCC GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 257. GCC GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 259. GCC GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 260. GCC GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. G7 GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. G7 GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. G7 GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 294. G7 GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 296. G7 GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 297. G7 GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. G7 GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 299. G7 GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 301. G7 GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 302. G7 GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. NATO GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 305. NATO GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. NATO GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 308. NATO GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 309. NATO GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 310. NATO GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 311. NATO GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. NATO GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 313. NATO GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 314. NATO GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 315. NATO GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 316. NATO GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 317. NATO GENOME ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. GLOBAL GENOME ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES GENOME ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY CRISPR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY AGRICULTURE & ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY INDUSTRIAL BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES GENOME ENGINEERING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES GENOME ENGINEERING MA